Skip to main content
OpenTrials
Completed

NCT Number: NCT00388011

Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery

Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray (MNS075) 3.75 mg, 7.5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7.5 mg, or IN placebo in patients with moderate to severe post-surgical pain following orthopedic surgery. After initial dosing, up to six (6) doses of IN MNS075 7.5 mg or 15 mg for up to twenty-four (24) hours will be evaluated. The rescue dose remained the same for each.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Diagnosis and Main Criteria for Inclusion:

Healthy adult patients (18 to 76 years old), who scored PS-1 to PS-3 according to the American Society of Anesthesiologists Physical Status Classification System, requiring primary, unilateral, first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair without additional collateral procedures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Requires primary unilateral first metatarsal bunionectomy surgery alone or with ipsilateral hammertoe repair under regional anesthesia. The patient requires collateral orthopedic surgical procedures other than ipsilateral hammertoe repair may not be enrolled into the study.
  • 18 years of age or older
  • Moderate to severe pain within eight (8) hours following completion of the required bunionectomy surgery

Exclusion criteria

  • Allergy to shellfish
  • Signs of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal drip of any etiology or any clinically significant nasal pathology that may affect the absorption of study medication or the assessment of safety.
  • Chronic respiratory insufficiency such that treatment with an opioid analgesic is contraindicated

Additional Inclusion/Exclusion Criteria May Apply

Treatment and study plan

Intranasal Morphine (MNS075) 3.75 mg

Drug

Intranasal Morphine (MNS075) 3.75 mg

Intravenous Morphine 7.5 mg

Drug

Intravenous Morphine 7.5 mg

Intranasal morphine (MNS075) 7.5 mg

Drug

Intranasal morphine (MNS075) 7.5 mg

Intranasal morphine (MNS075) 15 mg

Drug

Intranasal morphine (MNS075) 15 mg

Intranasal morphine (MNS075) 30 mg

Drug

Intranasal morphine (MNS075) 30 mg

Intranasal placebo

Drug

Intranasal placebo

Primary outcomes

  1. VAS Total Pain Relief 0-4 hours (TOTPAR4)

    Time frame: 4 hours

Secondary outcomes

  1. Other measures of pain relief

    Time frame: Several time points

Sponsors and collaborators

Lead sponsor

Javelin Pharmaceuticals

Industry

Registry information

Official study title

Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery

Important dates

Study start
2005
Primary completion
2005
Study completion
2005
First posted
Oct 13, 2006
Registry last updated
Jan 14, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.